212 related articles for article (PubMed ID: 36227345)
1. [New treatment options for metastatic HER2-low breast cancer : Consequences for histopathological diagnosis].
Denkert C; Lebeau A; Schildhaus HU; Jackisch C; Rüschoff J
Pathologie (Heidelb); 2022 Nov; 43(6):457-466. PubMed ID: 36227345
[TBL] [Abstract][Full Text] [Related]
2. New treatment options for metastatic HER2-low breast cancer : Consequences for histopathological diagnosis.
Denkert C; Lebeau A; Schildhaus HU; Jackisch C; Rüschoff J
Pathologie (Heidelb); 2023 Nov; 44(Suppl 2):53-60. PubMed ID: 36472635
[TBL] [Abstract][Full Text] [Related]
3. HER2-Low Breast Cancer-Diagnostic Challenges and Opportunities for Insights from Ongoing Studies: A Podcast.
Bardia A; Viale G
Target Oncol; 2023 May; 18(3):313-319. PubMed ID: 37133651
[TBL] [Abstract][Full Text] [Related]
4. Implementing antibody-drug conjugates (ADCs) in HER2-positive breast cancer: state of the art and future directions.
Ferraro E; Drago JZ; Modi S
Breast Cancer Res; 2021 Aug; 23(1):84. PubMed ID: 34380530
[TBL] [Abstract][Full Text] [Related]
5. Trastuzumab deruxtecan for HER2+ advanced breast cancer.
Lee J; Park YH
Future Oncol; 2022 Jan; 18(1):7-19. PubMed ID: 34823373
[TBL] [Abstract][Full Text] [Related]
6. Trastuzumab deruxtecan (DS-8201) in patients with HER2-expressing metastatic colorectal cancer (DESTINY-CRC01): a multicentre, open-label, phase 2 trial.
Siena S; Di Bartolomeo M; Raghav K; Masuishi T; Loupakis F; Kawakami H; Yamaguchi K; Nishina T; Fakih M; Elez E; Rodriguez J; Ciardiello F; Komatsu Y; Esaki T; Chung K; Wainberg Z; Sartore-Bianchi A; Saxena K; Yamamoto E; Bako E; Okuda Y; Shahidi J; Grothey A; Yoshino T;
Lancet Oncol; 2021 Jun; 22(6):779-789. PubMed ID: 33961795
[TBL] [Abstract][Full Text] [Related]
7. A review of treatment options in HER2-low breast cancer and proposed treatment sequencing algorithm.
Roy AM; Kumarasamy VM; Dhakal A; O'Regan R; Gandhi S
Cancer; 2023 Sep; 129(18):2773-2788. PubMed ID: 37349954
[TBL] [Abstract][Full Text] [Related]
8. HER2 Low Breast Cancer: A New Subtype or a Trojan for Cytotoxic Drug Delivery?
Popović M; Silovski T; Križić M; Dedić Plavetić N
Int J Mol Sci; 2023 May; 24(9):. PubMed ID: 37175916
[TBL] [Abstract][Full Text] [Related]
9. HER2-Overexpressing/Amplified Breast Cancer as a Testing Ground for Antibody-Drug Conjugate Drug Development in Solid Tumors.
Pegram MD; Miles D; Tsui CK; Zong Y
Clin Cancer Res; 2020 Feb; 26(4):775-786. PubMed ID: 31582515
[TBL] [Abstract][Full Text] [Related]
10. [New approval: Trastuzumab-deruxtecan for metastatic breast cancer HER2].
Minot-This MS; Bellesoeur A
Bull Cancer; 2021 Sep; 108(9):783-784. PubMed ID: 34144792
[No Abstract] [Full Text] [Related]
11. Safety, pharmacokinetics, and antitumour activity of trastuzumab deruxtecan (DS-8201), a HER2-targeting antibody-drug conjugate, in patients with advanced breast and gastric or gastro-oesophageal tumours: a phase 1 dose-escalation study.
Doi T; Shitara K; Naito Y; Shimomura A; Fujiwara Y; Yonemori K; Shimizu C; Shimoi T; Kuboki Y; Matsubara N; Kitano A; Jikoh T; Lee C; Fujisaki Y; Ogitani Y; Yver A; Tamura K
Lancet Oncol; 2017 Nov; 18(11):1512-1522. PubMed ID: 29037983
[TBL] [Abstract][Full Text] [Related]
12. Novel HER2-Targeting Antibody-Drug Conjugates of Trastuzumab Beyond T-DM1 in Breast Cancer: Trastuzumab Deruxtecan(DS-8201a) and (Vic-)Trastuzumab Duocarmazine (SYD985).
Xu Z; Guo D; Jiang Z; Tong R; Jiang P; Bai L; Chen L; Zhu Y; Guo C; Shi J; Yu D
Eur J Med Chem; 2019 Dec; 183():111682. PubMed ID: 31563805
[TBL] [Abstract][Full Text] [Related]
13. Trastuzumab deruxtecan (DS-8201a) in patients with advanced HER2-positive breast cancer previously treated with trastuzumab emtansine: a dose-expansion, phase 1 study.
Tamura K; Tsurutani J; Takahashi S; Iwata H; Krop IE; Redfern C; Sagara Y; Doi T; Park H; Murthy RK; Redman RA; Jikoh T; Lee C; Sugihara M; Shahidi J; Yver A; Modi S
Lancet Oncol; 2019 Jun; 20(6):816-826. PubMed ID: 31047803
[TBL] [Abstract][Full Text] [Related]
14. Trastuzumab deruxtecan in metastatic breast cancer with variable HER2 expression: the phase 2 DAISY trial.
Mosele F; Deluche E; Lusque A; Le Bescond L; Filleron T; Pradat Y; Ducoulombier A; Pistilli B; Bachelot T; Viret F; Levy C; Signolle N; Alfaro A; Tran DTN; Garberis IJ; Talbot H; Christodoulidis S; Vakalopoulou M; Droin N; Stourm A; Kobayashi M; Kakegawa T; Lacroix L; Saulnier P; Job B; Deloger M; Jimenez M; Mahier C; Baris V; Laplante P; Kannouche P; Marty V; Lacroix-Triki M; Diéras V; André F
Nat Med; 2023 Aug; 29(8):2110-2120. PubMed ID: 37488289
[TBL] [Abstract][Full Text] [Related]
15. [Not Available].
Deluche É; Vincent-Salomon A
Bull Cancer; 2021 Dec; 108(11S):11S1-11S7. PubMed ID: 34969511
[TBL] [Abstract][Full Text] [Related]
16. Trastuzumab Deruxtecan: Changing the Destiny of HER2 Expressing Solid Tumors.
Indini A; Rijavec E; Grossi F
Int J Mol Sci; 2021 Apr; 22(9):. PubMed ID: 33946310
[TBL] [Abstract][Full Text] [Related]
17. Trastuzumab Deruxtecan (DS-8201a): The Latest Research and Advances in Breast Cancer.
Andrikopoulou A; Zografos E; Liontos M; Koutsoukos K; Dimopoulos MA; Zagouri F
Clin Breast Cancer; 2021 Jun; 21(3):e212-e219. PubMed ID: 32917537
[TBL] [Abstract][Full Text] [Related]
18. Development and biological assessment of MMAE-trastuzumab antibody-drug conjugates (ADCs).
Yaghoubi S; Gharibi T; Karimi MH; Sadeqi Nezhad M; Seifalian A; Tavakkol R; Bagheri N; Dezhkam A; Abdollahpour-Alitappeh M
Breast Cancer; 2021 Jan; 28(1):216-225. PubMed ID: 32889587
[TBL] [Abstract][Full Text] [Related]
19. HER2-Low Breast Cancer: a New Subtype?
Corti C; Giugliano F; Nicolò E; Tarantino P; Criscitiello C; Curigliano G
Curr Treat Options Oncol; 2023 May; 24(5):468-478. PubMed ID: 36971965
[TBL] [Abstract][Full Text] [Related]
20. Navigating the HER2-Low Paradigm in Breast Oncology: New Standards, Future Horizons.
Tarantino P; Curigliano G; Tolaney SM
Cancer Discov; 2022 Sep; 12(9):2026-2030. PubMed ID: 35856622
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]